We agree with Spiegel and colleagues that our findings are not broadly generalisable1 since, as we noted,2 they relate to a single sponsor whose policy is to publish all human drug trials regardless of outcome. Although we hypothesised there would be no submission bias (according to the policy), it was not a given that policy would translate into practice. By sharing our data we hope to …
